This document is a publication of a European patent application (EP4549563A1) for a novel hyaluronidase Hyal1 variant developed by Odysgen Inc. The variant is characterized by its activity in neutral pH conditions, which could have implications for drug delivery and therapeutic applications.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in research and development of enzyme-based therapeutics or drug delivery systems. Companies should monitor patent landscapes for potential intellectual property considerations.